Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial

BACKGROUND: PDGFRA D842V mutations occur in 5–10% of gastrointestinal stromal tumours (GISTs), and previously approved tyrosine kinase inhibitors (TKIs) are inactive against this mutation. Consequently, patients have a poor prognosis. We present an updated analysis of avapritinib efficacy and long-t...

Descripción completa

Detalles Bibliográficos
Autores principales: Jones, Robin L., Serrano, César, von Mehren, Margaret, George, Suzanne, Heinrich, Michael C., Kang, Yoon-Koo, Schöffski, Patrick, Cassier, Philippe A., Mir, Olivier, Chawla, Sant P., Eskens, Ferry A.L.M., Rutkowski, Piotr, Tap, William D., Zhou, Teresa, Roche, Maria, Bauer, Sebastian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9518931/
https://www.ncbi.nlm.nih.gov/pubmed/33465704
http://dx.doi.org/10.1016/j.ejca.2020.12.008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9518931/
https://www.ncbi.nlm.nih.gov/pubmed/33465704
http://dx.doi.org/10.1016/j.ejca.2020.12.008

Ejemplares similares